MEK inhibitors in non-V600 BRAF mutations and fusions
MEK inhibitors in non-V600 BRAF mutations and fusions |
|
https://doi.org/10.18632/oncotarget.27788
Douglas B. Johnson,
Caroline A. Nebhan,
and Marcus S. Noel
|
| 3900-3903 |
Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells
Methylation of a newly identified region of the INS-IGF2 gene determines IGF2 expression in breast cancer tumors and in breast cancer cells |
|
https://doi.org/10.18632/oncotarget.27655
Vinodh Kumar Radhakrishnan,
Kameswaran Ravichandran,
Chibuzo Eke,
Amanda Ortiz-Vicil,
Qianwei Tan,
Marino De León,
and Daisy D. De León
|
| 3904-3920 |
MEK is a promising target in the basal subtype of bladder cancer
MEK is a promising target in the basal subtype of bladder cancer |
|
https://doi.org/10.18632/oncotarget.27767
Nathan M. Merrill,
Nathalie M. Vandecan,
Kathleen C. Day,
Phillip L. Palmbos,
Mark L. Day,
Aaron M. Udager,
Sofia D. Merajver,
and Matthew B. Soellner
|
| 3921-3932 |
Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells
Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells |
|
https://doi.org/10.18632/oncotarget.27782
Noymi Yam,
Jason Levin,
Zhengzheng Bao,
Wubin Qian,
and Victor A. Levin
|
| 3933-3942 |
Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model
Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model |
|
https://doi.org/10.18632/oncotarget.27769
Robert A. Kazmierczak,
Bakul Dhagat-Mehta,
Elke Gulden,
Li Lee,
Lixin Ma,
Clintin P. Davis-Stober,
Austen A. Barnett,
and Chiswili Yves Chabu
|
| 3943-3958 |
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas |
|
https://doi.org/10.18632/oncotarget.27784
Geraldine O'Sullivan Coyne,
Shivaani Kummar,
Robert S. Meehan,
Khanh Do,
Jerry M. Collins,
Larry Anderson,
Kazusa Ishii,
Naoko Takebe,
Jennifer Zlott,
Lamin Juwara,
Richard Piekarz,
Howard Streicher,
Elad Sharon,
Larry Rubinstein,
Andrea Regier Voth,
Jay Lozier,
Angie B. Dull,
Deborah Wilsker,
Toshinori Hinoue,
Peter W. Laird,
Katherine V. Ferry-Galow,
Robert J. Kinders,
Ralph E. Parchment,
James H. Doroshow,
and Alice P. Chen
|
| 3959-3971 |
Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors
Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors |
|
https://doi.org/10.18632/oncotarget.27772
Michael R. Mortensen,
Jacqueline Mock,
Marco Bertolini,
Marco Stringhini,
Marco Catalano,
and Dario Neri
|
| 3972-3983 |
Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma
Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.27775
Rikio Suzuki,
Yuka Kitamura,
Yoshihiko Nakamura,
Hibiki Akashi,
Yoshiaki Ogawa,
Hiroshi Kawada,
and Kiyoshi Ando
|
| 3984-3997 |
Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections
Histo-molecular differentiation of renal cancer subtypes by mass spectrometry imaging and rapid proteome profiling of formalin-fixed paraffin-embedded tumor tissue sections |
|
https://doi.org/10.18632/oncotarget.27787
Uwe Möginger,
Niels Marcussen,
and Ole N. Jensen
|
| 3998-4015 |
Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies |
|
https://doi.org/10.18632/oncotarget.27790
Michael E. Clark,
Helen Rizos,
Michelle R. Pereira,
Ashleigh C. McEvoy,
Gabriela Marsavela,
Leslie Calapre,
Katie Meehan,
Olivia Ruhen,
Muhammad A. Khattak,
Tarek M. Meniawy,
Georgina V. Long,
Matteo S. Carlino,
Alexander M. Menzies,
Michael Millward,
Melanie Ziman,
and Elin S. Gray
|
| 4016-4027 |
Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11–Rad50–Nbs1 complex in the repair of cisplatin-induced DNA cross-links
Evidence for functional and regulatory cross-talk between Wnt/β-catenin signalling and Mre11–Rad50–Nbs1 complex in the repair of cisplatin-induced DNA cross-links |
|
https://doi.org/10.18632/oncotarget.27777
Sanjeev Pasadi,
and Kalappa Muniyappa
|
| 4028-4044 |
Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine
Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine |
|
https://doi.org/10.18632/oncotarget.27785
Niraj Lodhi,
Moe Tun,
Poonam Nagpal,
Arati A. Inamdar,
Nehad M. Ayoub,
Noor Siyam,
Lucia Oton-Gonzalez,
Angela Gerona,
Dainelle Morris,
Rana Sandhu,
and Kwangsun Stephen Suh
|
| 4045-4073 |
Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling
Correction: Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling |
|
https://doi.org/10.18632/oncotarget.27779
Bridgette F. Peake,
Siobhan M. Eze,
Lily Yang,
Robert C. Castellino,
and Rita Nahta
|
| 4074-4075 |
